HIV-associated brain dysfunction in the era of HAART: reasons for hope, but continued concern.
Cohen
Ronald A
RA
Gongvatana
Assawin
A
D015526:AIDS Dementia Complex / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology*; D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data* / Q000639:trends; D001284:Atrophy / Q000188:drug therapy / Q000503:physiopathology / Q000821:virology; D001921:Brain / Q000473:pathology* / Q000503:physiopathology / Q000821:virology*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003072:Cognition Disorders / Q000188:drug therapy / Q000503:physiopathology / Q000821:virology; D004351:Drug Resistance / Q000276:immunology; D004734:Energy Metabolism / Q000502:physiology; D006801:Humans; D009474:Neurons / Q000378:metabolism / Q000473:pathology / Q000821:virology; D017063:Outcome Assessment, Health Care / Q000379:methods; D020127:Recovery of Function / Q000187:drug effects / Q000276:immunology; D013997:Time Factors; D017211:Treatment Failure; D019562:Viral Load